Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
WEBAvalyn Pharma has started a Phase 2b clinical trial testing the safety and efficacy of AP01, its investigational inhaled formulation of pirfenidone, in adults with progressive pulmonary fibrosis (PF). The MIST trial (NCT06329401) is expected to enroll 300 progressive PF patients, who will receive either one of….
New prototype therapy may repair IPF lung scarring by …
WEBby Steve Bryson, PhD April 26, 2024. Researchers have developed an inhalable prototype medicine that may be able to repair lung scarring caused by idiopathic pulmonary fibrosis (IPF) by stimulating the growth of stem cells directly in the lungs, a study reports. The study provides pharmacological proof of concept for an upcoming Phase 1 ...
BMS-986278 declared breakthrough therapy for progressive PF
WEBOct 27, 2023 · The FDA’s decision to grant breakthrough therapy designation to BMS-986278 was based on results from a global Phase 2 clinical trial (NCT04308681) assessing the safety and efficacy of BMS-986278 in 278 people with idiopathic PF (IPF) and progressive PF. Patients were assigned randomly to receive either 30 or 60 mg of the therapy, or a placebo ...
Study: ENV-101 improves IPF lung function, reverses fibrosis
WEBby Andrea Lobo June 7, 2024. Endeavor BioMedicines ’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The results, which also showed the treatment had an acceptable tolerability profile, were presented in a late ...
IPF Patients Live Longer on Ofev Compared with Placebo, Analysis …
WEBApr 16, 2019 · The analysis included data collected from a total of 1,126 IPF patients (mean age of 66.9 years), who were treated twice daily with 150 mg of Ofev, and 565 patients treated with a placebo. Participants received the treatment for a mean period of 27.7 months, with some patients receiving the treatment for a maximum of 93.1 months.
Esbriet, Ofev Found to Benefit IPF Patients in Clinical Practice
WEBApr 6, 2021 · Two approved anti-fibrotics are proving to be safe and effective in treating idiopathic pulmonary fibrosis (IPF), a study with real-world data reports. The data showed Esbriet (pirfenidone) and Ofev (nintedanib) increased progression-free survival, slowed down lung function decline, and reduced mortality in IPF patients.
First Patient Enrolled in Phase 3 Trial Testing BI 1015550
WEBOct 28, 2022 · by Steve Bryson, PhD October 28, 2022. Boehringer Ingelheim has enrolled the first patient in FIBRONEER-IPF, a Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of BI 1015550, an investigational therapy for people with idiopathic pulmonary fibrosis (IPF). The trial is part of the FIBRONEER global program, which also ...
Saracatinib as Effective, or Superior to Ofev, Esbriet in IPF...
WEBAug 30, 2022 · Saracatinib worked as well or better than Ofev or Esbriet at reducing tissue scarring, or fibrosis, in cell and animal models of IPF, a study showed.. The oral therapy was identified as an IPF treatment candidate based on a computational approach that analyzed the potential anti-fibrotic effects of several medications developed for …
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
WEBRecent Posts. Immune cells separate IPF, fibrotic hypersensitivity pneumonitis September 6, 2024; Tales of 2 women, both named Melissa, on their IPF journeys September 3, 2024; Patient journeys highlighted for this year’s PF Awareness Month August 30, 2024 ‘You can’t have that’: The diet restrictions since my transplant August 27, 2024; Phase 1b trial launched of inhaled nintedanib for ...
Oral BMS-986278 slows lung decline in progressive PF, Phase 2...
WEBSep 25, 2023 · These findings are consistent with previously reported data from a group of idiopathic pulmonary fibrosis (IPF) patients also participating in the clinical trial, whose lung function decline decreased by 62% with treatment at that dose.. Study results support moving BMS-986278 into global Phase 3 testing in a trial program being called ALOFT, according to the therapy’s developer, Bristol ...
Skip to content